|
02 Sep 2021 |
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
|
|
01 Sep 2021 |
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
|
|
01 Sep 2021 |
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
|
|
01 Sep 2021 |
Entos Pharmaceuticals' COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa
|
|
01 Sep 2021 |
Asher Bio Closes $108 Million Series B Financing
|
|
01 Sep 2021 |
Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
|
|
01 Sep 2021 |
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
|
|
01 Sep 2021 |
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
|
|
31 Aug 2021 |
HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376
|
|
31 Aug 2021 |
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
|
|
31 Aug 2021 |
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
|
|
31 Aug 2021 |
Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
|
|
31 Aug 2021 |
Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study
|
|
31 Aug 2021 |
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
|
|
31 Aug 2021 |
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
|
|
31 Aug 2021 |
Bayer starts Phase III clinical development program OASIS with Elinzanetant
|
|
31 Aug 2021 |
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
|
|
31 Aug 2021 |
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
|
|
31 Aug 2021 |
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
|
|
31 Aug 2021 |
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
|
